# Nanomaterial‐Enhanced Electrochemical Sensors for Clinical Monitoring of Acyclovir: Integration Into Molecular Diagnostics

## TL;DR

This paper explores nanomaterial-based sensors to improve acyclovir monitoring for better herpes virus treatment and patient safety.

## Contribution

The study introduces novel nanomaterial-enhanced electrochemical micro-devices for precise acyclovir detection.

## Key findings

- Nanomaterial-based sensors show improved detection capabilities and sensitivity for acyclovir.
- These devices can help optimize dosing and reduce risks in immunocompromised patients.
- The technology offers a new approach to enhance herpes virus treatment outcomes.

## Abstract

This study investigates the innovative application of nanomaterial‐based micro‐devices aimed at enhancing the diagnosis and management of acyclovir (ACV) for herpes virus infections, specifically those caused by HSV‐1, HSV‐2, CMV, and VZV.

Herpes viruses are associated with various clinical diseases, highlighting the urgent need for effective antiviral therapies. Acyclovir remains a primary treatment option; however, its potential for kidney toxicity and allergic reactions necessitates careful dosage monitoring, particularly in immunocompromised patients.

Recent advancements in drug monitoring systems have been developed to optimize dosing regimens and reduce the risk of misuse. This study focuses on the integration of biological and electrochemical nanosensors utilizing nanomaterials, which have shown significant improvements in detection capabilities and diagnostic sensitivity for ACV.

We delineate the novel features and applications of these micro‐devices, emphasizing their unique configurations and unprecedented limits of detection.

This research illustrates how these advanced technologies can enhance existing methodologies in herpes virus management, ultimately leading to improved treatment outcomes.

Schematic illustration of biosensor technology for detection of ACV.